Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Anna Rochelle Schreiber

TitleAssistant Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schreiber AR, Smoots SG, Jackson MM, Bagby SM, Dus ED, Dominguez ATA, Binns CA, Pitts TM, Diamond JR. Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Front Oncol. 2025; 15:1549282. PMID: 40242242.
      View in: PubMed
    2. Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez ATA, Dus ED, Binns CA, MacBeth M, Whitty PA, Diamond JR, Pitts TM. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis. Breast Cancer Res. 2024 03 01; 26(1):35. PMID: 38429789.
      View in: PubMed
    3. Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM, Martin A, DeMattei JA, Holay N, Triplett TA, Eckhardt SG, Litwiler K, Winkler J, Piscopio AD, Diamond JR. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers (Basel). 2023 Dec 23; 16(1). PMID: 38201519.
      View in: PubMed
    4. Roy S, Lakritz S, Schreiber AR, Kuna EM, Bradley CJ, Kondapalli L, Diamond JR. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study. Eur J Cancer. 2024 Jan; 196:113426. PMID: 38000217.
      View in: PubMed
    5. Schreiber AR, O'Bryant CL, Kabos P, Diamond JR. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther. 2023 Jul-Dec; 23(10):1061-1069. PMID: 37742278.
      View in: PubMed
    6. Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimar?es-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, Aisner DL, Gutman JA. A Case of Fetal-Induced Graft-versus-Host Disease. N Engl J Med. 2023 08 17; 389(7):668-670. PMID: 37585636.
      View in: PubMed
    7. Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 05; 185:69-82. PMID: 36965330.
      View in: PubMed
    8. Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JR. Evaluating anthracycline?+?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022 Jan; 191(2):389-399. PMID: 34705147.
      View in: PubMed
    9. Schreiber AR, Andress M, Diamond JR. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Rev Anticancer Ther. 2021 12; 21(12):1303-1311. PMID: 34651524.
      View in: PubMed
    10. Schreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, Kabos P, Diamond JR. Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. Front Oncol. 2021; 11:640690. PMID: 33816286.
      View in: PubMed
    11. Schreiber AR, Kar A, Goodspeed AE, Pozdeyev N, Somerset H, Raeburn CD, Tan AC, Leong S, Wierman ME, Kiseljak-Vassiliades K. Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report. J Endocr Soc. 2020 Mar 01; 4(3):bvaa017. PMID: 32154490.
      View in: PubMed
    12. Schreiber AR, Nguyen A, Bagby SM, Arcaroli JJ, Yacob BW, Quackenbush K, Guy JL, Crowell T, Stringer B, Danaee H, Kalebic T, Messersmith WA, Pitts TM. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clin Cancer Drugs. 2018; 5(1):42-49. PMID: 30631747.
      View in: PubMed
    13. Greene J, Nguyen A, Bagby SM, Jones GN, Tai WM, Quackenbush KS, Schreiber A, Messersmith WA, Devaraj KM, Blatchford P, Eckhardt SG, Cadogan EB, Hughes GD, Smith A, Pitts TM, Arcaroli JJ. The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. Oncotarget. 2017 Dec 19; 8(67):110904-110913. PMID: 29340025.
      View in: PubMed
    14. Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, Kim J, Wang G, Purkey A, Pitts TM, Nguyen A, Gao D, Blatchford P, Capasso A, Schuller AG, Eckhardt SG, Arcaroli JJ. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget. 2016 May 10; 7(19):28273-85. PMID: 27070088.
      View in: PubMed
    Schreiber's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (45) concept(s)
    _
    Co-Authors Expand Description
    See all (32) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)